Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATALYST: CyPep-1 plus pembrolizumab in advanced solid tumors
NL-OMON51302Phase 2Withdrawn
- Sponsor
- Cytovation
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cypep-1 and pembrolizumab in head and neck squamous cell carcinoma (HNSCC), melanoma and triple-negative breast cancer (TNBC) (3 arms), sponsored by Cytovation. Primary endpoints: Treatment-emergent adverse events, Dose-limiting toxicities and 2 more. Planned start Jul 2022; status: withdrawn.
02
Drugs
cypep-1pembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)melanomatriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON51302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51302.